211 related articles for article (PubMed ID: 37310796)
1. Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism.
Ullah F; Song J; Rojas Hernandez CM; Kroll MH; Escalante CP; Toale KM
Oncologist; 2023 Nov; 28(11):e1005-e1016. PubMed ID: 37310796
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism.
Recio-Boiles A; Veeravelli S; Vondrak J; Babiker HM; Scott AJ; Shroff RT; Patel H; Elquza E; McBride A
World J Gastrointest Oncol; 2019 Oct; 11(10):866-876. PubMed ID: 31662825
[TBL] [Abstract][Full Text] [Related]
3. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Robertson L; Yeoh SE; Ramli A
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
5. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies.
Fredman D; McNeil R; Eldar O; Leader A; Gafter-Gvili A; Avni T
J Thromb Thrombolysis; 2024 Mar; 57(3):453-465. PubMed ID: 38127261
[TBL] [Abstract][Full Text] [Related]
7. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
10. Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism.
Chen J; Bi G; Wu F; Qin X
Pediatr Res; 2023 May; 93(6):1491-1498. PubMed ID: 36071237
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
12. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis.
Vasanthamohan L; Boonyawat K; Chai-Adisaksopha C; Crowther M
J Thromb Haemost; 2018 Jul; 16(7):1288-1295. PubMed ID: 29772108
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France.
Bertoletti L; Gusto G; Khachatryan A; Quignot N; Chaves J; Moniot A; Mokgokong R
Thromb Haemost; 2022 Aug; 122(8):1384-1396. PubMed ID: 34983073
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis.
Ning H; Yang N; Ding Y; Chen H; Wang L; Han Y; Cheng G; Zou M
Med Clin (Barc); 2023 Mar; 160(6):245-252. PubMed ID: 36031454
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis.
Elsebaie MAT; van Es N; Langston A; Büller HR; Gaddh M
J Thromb Haemost; 2019 Apr; 17(4):645-656. PubMed ID: 30690830
[TBL] [Abstract][Full Text] [Related]
17. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban for cancer-associated venous thromboembolism.
Liang B; Liang Y; Zhao LZ; Zhao YX; Gu N
Sci Prog; 2021; 104(2):368504211012160. PubMed ID: 33913387
[TBL] [Abstract][Full Text] [Related]
20. Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up.
Laganà A; Assanto GM; Masucci C; Passucci M; Donzelli L; Serrao A; Baldacci E; Santoro C; Chistolini A
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024020. PubMed ID: 38468835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]